The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 12, 2007, Pages 5708-5715

  Ameri, Hossein ^a,c   Chader, Gerald J ^a   Kim, June Gone ^a,b   Sadda, SriniVas R ^a   Rao, Narsing A ^a   Humayun, Mark S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c DOHENY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EOSIN; FLUORESCEIN; HEMATOXYLIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENUCLEATION; EXPERIMENTAL RABBIT; EYE FUNDUS; EYE PHOTOGRAPHY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HYPEREMIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA CAPILLARY; RETINA NEOVASCULARIZATION; VASODILATATION; ANIMAL; CAPILLARY; CAPILLARY PERMEABILITY; DISEASE MODEL; DRUG ANTAGONISM; INJECTION; METABOLISM; OPTIC DISK; PATHOLOGY; RABBIT; RETINA BLOOD VESSEL; VASCULARIZATION; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CAPILLARIES; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; FLUORESCEIN; FLUORESCEIN ANGIOGRAPHY; HYPEREMIA; INJECTIONS; OPTIC DISK; RABBITS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 38549123431     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0731     Document Type: Article

References (50)

1. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246(4935):1309-1312.
2. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84(5):1470-1478.
3. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-985.
4. Miller JW. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol. 1997;151(1):13-23.
5. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90(12): 1542-1547.
6. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005:25(2):111-118.
7. Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res. 2006;83(5):1005-1016.
8. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242-248.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487.
10. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol. 1996;80(4):363-366.
11. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281(10):6625-6631.
12. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002;9(suppl 2):36-44.
13. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32(1):1-14.
14. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreous injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36(4):336-339.
15. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreous injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331-335.
16. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275-278.
17. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26(3): 352-354.
18. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26(3):354-356.
19. Mason JO 3rd, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina. 2006;26(3):356-357.
20. Siqueira RC, Costa RA, Scott IU, et al. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand. 2006;84(6):834-835.
21. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26(9):999-1005.
22. Finger PT. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol. 2007;143(2):335-338.
23. Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007; 114(8):1174-1179.
24. Jorge R, Costa RA, Calucci D, Scott IU. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol. 2006;245(7):1045-1048.
25. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26(3):257-261.
26. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreous injection of bevacizumab (Avastin). Retina. 2006;26(3):262-269.
27. Bakri SJ, Cameron JD, McCannel CA, et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol. 2006;142(1):162-164.
28. Feiner L, Barr EE, Shui YB, et al. Safety of intravitreous injection of bevacizumab in rabbit eyes. Retina. 2006;26(8):882-888.
29. Inan UU, Avci B, Kusbeci T, et al. Preclinical safety evaluation of intravitreous injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48(4):1773-881.
30. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreous injection of bevacizumab. Am J Ophthalmol. 2007;143(6):995-1002.
31. Ozaki H, Hayashi H, Vinores SA, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64(4):505-517.
32. Alikacem N, Yoshizawa T, Nelson KD, Wilson CA. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits. Invest Ophthalmol Vis Sci. 2000;41(6):1561-1569.
33. Wong CG, Rich KA, Liaw LH, et al. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr Eye Res. 2001;22(2):140-147.
34. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103(11):1820-1828.
35. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol. 2006;290(2):H547-H559.
36. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106(11):1311-1319.
37. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156(2):697-707.
38. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111(9):1287-1295.
39. Hofman P, van Blijswijk BC, Gaillard PJ, et al. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch Ophthalmol. 2001;119(6):861-866.
40. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol. 2002;133(3):373-385.
41. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998;125(9):1591-1588.
42. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103(2): 159-165.
43. Hellstrom M, Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999;126(14):3047-3055.
44. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168(6):2036-2053.
45. Zhang HT, Scott PA, Morbidelli L, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer. 2000; 83(1):63-68.
46. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109(3):227-241.
47. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996;271(13): 7788-7795.
48. Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992;267(36):26031-26037.
49. Ahmadieh H, Moradian S, Malihi M. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreous injection of bevacizumab. Int Ophthalmol. 2005;26(4-5):191-193.
50. Gibran SK, Sachdev A, Stappler T, et al. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br J Ophthalmol. 2007;91(5):602-604.